BDTX
Black Diamond Therapeutics Inc
NASDAQ: BDTX · HEALTHCARE · BIOTECHNOLOGY
$2.83
-5.74% today
Updated 2026-06-05
Market cap
$124.92M
P/E ratio
—
P/S ratio
2.11x
EPS (TTM)
$-0.77
Dividend yield
—
52W range
$2 – $5
Volume
1.3M
WallStSmart proprietary scores
34
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.0
Quality
B+3.0
Profitability
D5.0
Valuation
C+5/9
Piotroski F-Score
Moderate
-0.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$9.86
+248.41%
12-Month target
$2.19
-22.61%
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.17x — low leverage
Risks
- Altman Z -0.44 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-10.23M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $70.00M | $0.00 |
| Net income | $-91.17M | $-82.44M | $-69.68M | $22.37M | $-9.04M |
| EPS | — | — | — | — | $-0.77 |
| Free cash flow | $-85.27M | $-66.75M | $-62.30M | $29.61M | $-10.23M |
| Profit margin | — | — | — | 31.95% | — |
Peer comparison
Smart narrative
Black Diamond Therapeutics Inc trades at $2.83. Our Smart Value Score of 34/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -0.44, it sits in the distress.
Frequently asked questions
What is Black Diamond Therapeutics Inc's stock price?
Black Diamond Therapeutics Inc (BDTX) trades at $2.83, on a P/S of 2.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Black Diamond Therapeutics Inc overvalued?
Black Diamond Therapeutics Inc carries a Smart Value Score of 34/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Black Diamond Therapeutics Inc (BDTX)?
The 12-month analyst consensus target is $9.86, about 248.4% above the current $2.83. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Black Diamond Therapeutics Inc's Altman Z-Score is -0.44, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.11x
ROE-41.43%
Beta3.35
50D MA$2.65
200D MA$2.94
Shares out0.06B
Float0.05B
Short ratio—
Avg volume1.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—